ArticleOncology letters2025
Peripheral blood tumor marker levels can indicate the location of lung cancer metastasis.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development and validation of a machine-learning-based triage model incorporating systemic inflammatory, nutritional, coagulation, and tumor marker parameters for identifying baseline distant metastasis in lung cancer.Frontiers in oncology · 2026Article
- Case Report: Invasive mucinous adenocarcinoma mimicking interstitial pneumonia with autoimmune features: diagnostic pitfalls and reflections.Frontiers in immunology · 2026Article
- Development and validation of machine learning models based on blood routine tests and tumor markers in early screening of primary bronchogenic lung cancer.Translational lung cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection of lung cancer metastasis is of great importance for improving patient survival and reducing the economic and social burden of the disease. Omics analysis is widely used in the screening of tumor markers. However, effective markers that can indicate tumor metastasis in tissues and organs have not been screened out. The present study aimed to use the existing commonly used clinical tumor marker detection indicators to simply indicate possible metastatic organs through abnormal changes in their content. For this, three types of lung cancer, namely, lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC) and small cell lung cancer (SCLC), were selected for analysis. Patients of each type were grouped according to whether the tumor metastasized and whether it metastasized to a single tissue or organ, such as the lymph nodes, pleura, bones, liver and brain. The pre-treatment peripheral serum carcinoembryonic antigen (CEA), carbohydrate antigen (CA)15-3, CA125, CA19-9, squamous cell carcinoma (SCC) antigen and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) levels were recorded. The tumor markers that differed from the non-metastasis group were preliminarily determined by one-way analysis of variance, and the ROC curve method was used to determine the marker's ability to evaluate metastasis to a certain organ. In LUAD, compared with levels in patients without metastasis, CA15-3 and CA19-9 levels were significantly increased in the group with lymph node metastasis, only the CA15-3 level was significantly increased in the group with pleural metastasis, CEA, CA15-3 and CA125 levels were significantly increased in the group with bone metastasis, only the CA125 level was significantly increased in the group with liver metastasis and only the CYFRA21-1 level was significantly increased in the group with brain metastasis. Compared with that in LUAD without metastasis, CEA and CA15-3 had a good diagnostic effect on bone metastasis screening, and CYFRA21-1 also had a good diagnostic effect on brain metastasis. There was no significant difference in the levels of tumor markers in the peripheral blood of LUSC patients with tissue and organ metastasis. In SCLC, compared with levels in the control group, CEA and CA125 levels were significantly increased in patients with bone metastasis, and CA125 and CA19-9 levels were significantly increased in patients with liver metastasis. In SCLC tumors, CEA and CA125 exhibited good diagnostic value for determining bone metastasis. CA125 and CA19-9 also exhibited some diagnostic value for liver metastasis. In conclusion, the levels of peripheral blood tumor markers CEA, CA15-3, CA125, CA19-9, SCC and CYFRA21-1 in patients lung cancer have clinical diagnostic value in specifically indicating the organs where lung cancer metastasizes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.